DE602005023191D1 - Verfahren zur verbesserung der hämodynamischen stabilität mit sauerstoff-tragenden zusammensetzungen - Google Patents

Verfahren zur verbesserung der hämodynamischen stabilität mit sauerstoff-tragenden zusammensetzungen

Info

Publication number
DE602005023191D1
DE602005023191D1 DE602005023191T DE602005023191T DE602005023191D1 DE 602005023191 D1 DE602005023191 D1 DE 602005023191D1 DE 602005023191 T DE602005023191 T DE 602005023191T DE 602005023191 T DE602005023191 T DE 602005023191T DE 602005023191 D1 DE602005023191 D1 DE 602005023191D1
Authority
DE
Germany
Prior art keywords
oxygen
hemodynamic stability
relates
present
improving hemodynamic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005023191T
Other languages
English (en)
Inventor
Robert M Winslow
Kim D Vandegriff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangart Inc
Original Assignee
Sangart Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangart Inc filed Critical Sangart Inc
Publication of DE602005023191D1 publication Critical patent/DE602005023191D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
DE602005023191T 2004-08-31 2005-08-30 Verfahren zur verbesserung der hämodynamischen stabilität mit sauerstoff-tragenden zusammensetzungen Active DE602005023191D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60581604P 2004-08-31 2004-08-31
PCT/US2005/031257 WO2006026739A2 (en) 2004-08-31 2005-08-30 Methods to enhance hemodynamic stability using oxygen carrying compositions

Publications (1)

Publication Number Publication Date
DE602005023191D1 true DE602005023191D1 (de) 2010-10-07

Family

ID=38039091

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005023191T Active DE602005023191D1 (de) 2004-08-31 2005-08-30 Verfahren zur verbesserung der hämodynamischen stabilität mit sauerstoff-tragenden zusammensetzungen

Country Status (12)

Country Link
US (3) US20060172924A1 (de)
EP (1) EP1796694B1 (de)
JP (2) JP2008511674A (de)
KR (1) KR20070069154A (de)
CN (1) CN101039684A (de)
AT (1) ATE478674T1 (de)
AU (1) AU2005279780B2 (de)
CA (1) CA2578232C (de)
DE (1) DE602005023191D1 (de)
ES (1) ES2347805T3 (de)
MX (1) MX2007002187A (de)
WO (1) WO2006026739A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
ME02979B (de) 2009-06-09 2018-10-20 Prolong Pharmaceuticals Llc Hämoglobinzusammensetzungen
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
CA2791122C (en) 2010-02-25 2019-08-27 Sangart, Inc. Methods for preparing peg-hemoglobin conjugates using reduced reactant ratios
JP2015514086A (ja) * 2012-03-29 2015-05-18 サンガート， インコーポレイテッド ジアスピリン架橋ｐｅｇヘモグロビン
US9731957B2 (en) 2014-01-21 2017-08-15 Indian Institute Of Technology, Bombay Polymer anchored microelectromechanical system (MEMS) cantilever and method of fabricating the same
EP3655019A4 (de) 2017-07-18 2021-04-21 Virtech Bio, Inc. Hämoglobin enthaltende blutersatzstoffe und verfahren zu deren herstellung

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692054A (en) * 1970-02-09 1972-09-19 Fisher Controls Co Pneumatic relay
US3925344A (en) * 1973-04-11 1975-12-09 Community Blood Council Plasma protein substitute
US3925311A (en) * 1974-05-30 1975-12-09 Us Air Force Thermally stable aryloxybenzimidazobenzophenanthroline compositions
US4061736A (en) * 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4473496A (en) * 1981-09-14 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Intramolecularly crosslinked hemoglobin
US4529719A (en) * 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
US4600531A (en) * 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
JPS61116107A (ja) * 1984-11-09 1986-06-03 Hitachi Ltd アクチユエ−タの制御装置
US4584130A (en) * 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
US4826811A (en) * 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
US5194590A (en) * 1986-06-20 1993-03-16 Northfield Laboratories, Inc. Acellular red blood cell substitute
GB8710598D0 (en) * 1987-05-05 1987-06-10 Star Medical Diagnostics Ltd Hemoglobin based blood substitute
US5449759A (en) * 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
GB8711614D0 (en) * 1987-05-16 1987-06-24 Medical Res Council Proteins
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US5250665A (en) * 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation
US5814601A (en) 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
US6054427A (en) * 1997-02-28 2000-04-25 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
US6003428A (en) * 1998-07-24 1999-12-21 Smc Pneumatics, Inc. Electro-pneumatic pressure control system for welding and like apparatus
WO2001034648A1 (en) * 1999-11-12 2001-05-17 Baxter International, Inc. Reduced side-effect hemoglobin compositions
US20030153491A1 (en) * 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20040072729A1 (en) * 2002-10-10 2004-04-15 Sunbio Inc. High oxygen affinity PEG-hemoglobin as treatment for brain stroke
US7501499B2 (en) * 2002-12-23 2009-03-10 Albert Einstein College Of Medicine Of Yeshiva University Modified hemoglobin and methods of making same

Also Published As

Publication number Publication date
MX2007002187A (es) 2007-10-08
CN101039684A (zh) 2007-09-19
WO2006026739A3 (en) 2006-05-11
US20100087361A1 (en) 2010-04-08
JP2012207048A (ja) 2012-10-25
EP1796694B1 (de) 2010-08-25
CA2578232A1 (en) 2006-03-09
EP1796694A4 (de) 2009-08-26
US7622439B2 (en) 2009-11-24
ES2347805T3 (es) 2010-11-04
US20090075866A1 (en) 2009-03-19
AU2005279780B2 (en) 2011-02-03
US20060172924A1 (en) 2006-08-03
KR20070069154A (ko) 2007-07-02
CA2578232C (en) 2015-12-29
ATE478674T1 (de) 2010-09-15
US8278275B2 (en) 2012-10-02
AU2005279780A1 (en) 2006-03-09
JP2008511674A (ja) 2008-04-17
EP1796694A2 (de) 2007-06-20
WO2006026739A2 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
DE602005023191D1 (de) Verfahren zur verbesserung der hämodynamischen stabilität mit sauerstoff-tragenden zusammensetzungen
ATE456673T1 (de) Verfahren und zusammensetzungen zur messung von natriuretischen peptiden und verwendung dafür
ATE382358T1 (de) Verfahren und zusammensetzungen zum sauerstofftransport mit hoher sauerstoffaffinität
WO2008051689A3 (en) Nitric oxide-blocked cross-linked tetrameric hemoglobin
CR20220618A (es) Nuevas proteinas de unión a repeticiones de anquirina y sus usos
BRPI0514713A (pt) métodos para aumentar a estabilidade hemodinámica utilizando composições carreadoras de oxigênio
MXPA04004170A (es) Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9.
BRPI1103213B8 (pt) Composição de enxaguatório bucal antimicrobiano com teor alcoólico reduzido à base de óleo essencial bioativo
DE60330767D1 (de) Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen
ATE416789T1 (de) Kombinationen für die hcv-behandlung
EA201100071A1 (ru) Новые композиции и способы
NZ592837A (en) Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
ATE390142T1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
ATE367167T1 (de) Aufbereitung von aldesleukin zur pharmazeutischen verwendung
WO2006135493A3 (en) A composition for wound healing and use thereof
ATE319479T1 (de) Verfahren zur erhöhen der bioverfügbarkeit und dem eindringen in gefässe von azithromycin
NO20063106L (no) MRI-kontrastmediumsammensetning for oral administrasjon
SE0401631D0 (sv) New Composition
TW200744660A (en) Oral composition containing morin
BR112013007305A2 (pt) corpo cerâmico monolítico região marginal de óxido misto e superfície metálica, método para a sua produção e seu uso
WO2003103592A3 (en) COVALENT CONJUGATES BETWEEN ARTEMISININ-BOUND ENDOPEROXIDES AND IRON-CARRYING PROTEINS AND METHODS OF USE THEREOF
ATE408485T1 (de) Verfahren und mittel zur verbesserung der tränkmittelaufnahme und -verteilung in hölzern
DE602007010499D1 (de) Verfahren und zusammensetzungen für gentherapie
MY151438A (en) Compositions and method for treatment of tumors
DE602005013385D1 (de) Verwendung von Kollagen in Kombination mit Sauerstoff- und Ozon-freisetzenden Perfluorkohlenwasserstoffen zur Herstellung eines Medikaments zur Behandlung von Hautverletzungen